Publication | Open Access

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology